231,70 €
1,09 %gestern
L&S, 21. Februar, 22:54 Uhr
ISIN
US2358511028
Symbol
DHR
Berichte

Danaher Aktie News

Positiv
MarketBeat
etwa ein Monat alt
Danaher Corporation NYSE: DHR shares went into a tailspin when the Abcam deal came into question, but the dip turned out to be a buying opportunity in this life-sciences company. The dip hit bottom soon after, and even weak guidance could not lower the market.
Neutral
Seeking Alpha
etwa ein Monat alt
Danaher Corporation (DHR) 42nd Annual J.P. Morgan Healthcare Conference (Transcript)
Neutral
PRNewsWire
etwa ein Monat alt
New collaborative research center based at University of California, Berkeley, plans to develop platform approaches that can be easily modified to develop gene-editing medicines for hundreds of devastating illnesses Innovative model aims to dramatically reduce preclinical and clinical development time and expense for investigational rare disease therapies that currently struggle to attract fund...
Neutral
PRNewsWire
etwa ein Monat alt
WASHINGTON , Jan. 8, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") announced that its President and Chief Executive Officer, Rainer M. Blair, will comment tomorrow on the Company's fourth quarter 2023 performance in a presentation at the J.P.
Neutral
PRNewsWire
etwa 2 Monate alt
WASHINGTON , Jan. 2, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the J.P.
Positiv
CNBC
etwa 2 Monate alt
This year's list is a bit more defensive than in years past and has a focus on earnings growth.
Positiv
Seeking Alpha
etwa 2 Monate alt
Danaher has undergone a radical transformation from a real estate trust to a leader in the life sciences industry through strategic acquisitions. The company's focus on continuous improvement and efficiency, guided by the Kaizen philosophy, has been a driving force behind its success. Danaher's recent divestments and increased focus on its core businesses have led to strong financial performanc...
Positiv
Seeking Alpha
etwa 2 Monate alt
Danaher is my low-risk SWAN stock pick for 2024, with a strong track record of growth and a focus on rational, data-driven decision-making at its core. The end market for Danaher's healthcare and bioprocessing products is expected to return to growth, driven by new technology and increased funding. The spin-off of certain segments and potential future acquisitions, as well as operational improv...
Mehr News anzeigen

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen